

Stem Cells and Cancer Stem Cells 3  
Therapeutic Applications in Disease and Injury

---

M.A. Hayat  
*Editor*

# Stem Cells and Cancer Stem Cells

Volume 3  
Therapeutic Applications  
in Disease and Injury

 Springer

# Stem Cells and Cancer Stem Cells

Stem Cells and Cancer Stem Cells  
Volume 3

For other titles published in this series, go to  
[www.springer.com/series/10231](http://www.springer.com/series/10231)

Stem Cells and Cancer Stem Cells  
Volume 3

# Stem Cells and Cancer Stem Cells

Therapeutic Applications in Disease  
and Injury

Edited by

M.A. Hayat  
Distinguished Professor  
Department of Biological Sciences,  
Kean University, Union, NJ, USA

 Springer

*Editor*

M.A. Hayat  
Department of Biological Sciences  
Kean University  
Union, NJ, USA  
ehayat@kean.edu

ISBN 978-94-007-2414-3                      e-ISBN 978-94-007-2415-0  
DOI 10.1007/978-94-007-2415-0  
Springer Dordrecht Heidelberg London New York

Library of Congress Control Number: 2011933477

© Springer Science+Business Media B.V. 2012

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

“Although touched by technology, surgical pathology always has been, and remains, an art. Surgical pathologists, like all artists, depict in their artwork (surgical pathology reports) their interactions with nature: emotions, observations, and knowledge are all integrated. The resulting artwork is a poor record of complex phenomena.”

Richard J. Reed MD

## One Point of View

All small tumors do not always keep growing, especially small breast tumors, testicular tumors, and prostate tumors. Some small tumors may even disappear without a treatment. Indeed, because prostate tumor grows slowly, it is not unusual that a patient may die at an advanced age of some other causes, but prostate tumor is discovered in an autopsy study. In some cases of prostate tumors, the patient should be offered the option of active surveillance followed by PSA test or biopsies. Similarly, every small kidney tumor may not change or may even regress. Another example of cancer or precancer reversal is cervical cancer. Precancerous cervical cells found with Pap test, may revert to normal cells. Tumor shrinkage, regression, reversal, or stabilization is not impossible.

Another known example of cancer regression is found in pediatric neuroblastoma patients. Neuroblastoma shows one of the highest rates of spontaneous regression among malignant tumors. In addition to the well-known spontaneous regression in stage 4S disease, the high incidence of neuroblastoma remnants found during autopsy of newborns suggest that localized lesions may undergo a similar regression (Guin et al., 1969). Later studies also indicate that spontaneous regression is regularly seen in infants with localized neuroblastoma and is not limited to the first year of life (Hero et al., 2008). These and other studies justify the “wait and see” strategy, avoiding chemotherapy and radiotherapy in infants with localized neuroblastoma, unless *MYCN* gene is amplified. Infants with nonamplified *MYCN* and hyperdiploidy can be effectively treated with less intensive therapy. Infants with disseminated disease without *MYCN* have excellent survival with minimal or no treatment.

The pertinent question is: Is it always necessary to practice tumor surgery, radiotherapy, or chemotherapy? Although the conventional belief is that cancer represents an “arrow that advances unidirectionally”, it is becoming clear that for cancer to progress, they require cooperative microenvironment (niche), including immune system and hormone levels. However, it is emphasized that advanced (malignant) cancers do not show regression, and require therapy. In the light of the inadequacy of standard treatments of malignancy, clinical applications of the stem cell technology need to be expedited.

Eric Hayat

## References

- Guin P, Gilbert E, Jones B (1969) Incidental neuroblastoma in infants. *Am J Clin Pathol* 51:126–136
- Hero S, Simon T, Spitz R, Ernestus K, Gnekow A, Scheel-Walter H, Schwabe D, Schilling F, Benz-Bohm G, Berthold F (2008) Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB 97. *J Clin Oncol* 26:1504–1510



## Preface

This is Volume 3 of the seven-volume series, *Stem Cells and Cancer Stem Cells: Therapeutic Applications in Disease and Injury*. A stem cell is defined as a cell that can self-renew and differentiate into one or more specialized cell types. A stem cell may be pluripotent, which is able to give rise to the endodermal, ectodermal, and mesodermal lineages; an example is embryonic stem cells. A stem cell may be multipotent, which is able to give rise to all cells in a particular lineage; examples are hematopoietic stem cells and neural stem cells. A stem cell may be unipotent, which is able to give rise to only one cell type; an example is keratinocytes.

A cancer stem cell is a cell type within a tumor that possesses the capacity of self-renewal and can give rise to the heterogeneous lineages of cancer cells that comprise the tumor. In other words, a cancer stem cell is a tumor initiating cell. A unique feature of cancer stem cell is that although conventional chemotherapy will kill most cells in a tumor; cancer stem cells remain intact, resulting in the development of resistance of therapy. All of these types of stem cells are discussed in this volume. Vast applications of stem cells, cancer stem cells, mesenchymal stem cells, and pluripotent human stem cells are discussed.

As stated above, given that human embryonic stem cells possess the potential to produce unlimited quantities of any human cell type; considerable focus has been placed on their therapeutic potential. Because of the pluripotency of embryonic stem cells, they have been used in various applications such as tissue engineering, regenerative medicine, pharmacological and toxicological studies, and fundamental studies of cell differentiation. The formation of embryoid bodies, which are three-dimensional aggregates of embryonic stem cells, is the initial step in the differentiation of these cells. Embryonic stem cells can differentiate into derivatives of three germ layers: the endoderm, mesoderm, and ectoderm. Therefore, embryoid body culture has been widely used as a trigger for the in vitro differentiation of embryonic stem cells.

Support and development of the stem cell field, especially the applications of human embryonic stem cells, other embryonic stem cells, embryonic cortical neural stem cells, human cord blood-derived hematopoietic stem and progenitor cells, hair follicle stem cells, and corneal epithelial stem cells, in cancer and other diseases and tissue/organs repair (regeneration) are described. The damage or injury of living tissues is a major challenge during adult life in humans. Enhancing the regenerative potential of cells devoted to tissue repair (the stem cells) either endogenous or supplied from outside, is one of the most important challenges and developments in the medical field. This aspect of therapy is discussed in detail in this volume. Methods for culturing, isolation, and expansion of mesenchymal stem cells, hair follicle stem

cells, human embryonic stem cells, and corneal epithelial stem cells are detailed. Role of transcription factors in early embryonic development and primordial germ cell migration is also explained.

The role of hypoxia in embryonic cortical neural stem cell proliferation and differentiation and in stem cell distribution and MGMT expression in a glioblastoma tumor is included. The role of mutations in the initiation of tumorigenesis is clarified. Also, is explained the role of cancer stem cells of breast, colon, and melanoma tumors in response to antitumor therapy. Cell-based regenerative therapies, including for medical radiation burns, using mesenchymal stem cells are presented. The role of mechanical strain in promoting apoptosis and differentiation using mesenchymal stem cells is also explained.

The role of cancer stem cells, specifically in glioblastoma is explained. Transplantation of embryonic stem cells to reduce brain lesions is included. Transplantation of bone marrow-derived stem cells for myocardial infraction and use of mesenchymal stem cells in orthopedics are described. The complex role of stem cells in angiogenesis is detailed. Targeting of cancer stem cells is also included. Insights on the understanding of molecular pathways involved in tumor biology are explained, which lead to the development of effective drugs. Information on pathways (e.g., hedgehog) facilitates targeted therapies in cancer.

By bringing together a large number of experts (oncologists, neurosurgeons, physicians, research scientists, and pathologists) in various aspects of this medical field, it is my hope that substantial progress will be made against terrible human disease and injury. It is difficult for a single author to discuss effectively the complexity of diagnosis, therapy, including tissue regeneration. Another advantage of involving more than one author is to present different points of view on a specific controversial aspect of cancer cure and tissue regeneration. I hope these goals will be fulfilled in this and other volumes of the series. This volume was written by 106 contributors representing 16 countries. I am grateful to them for their promptness in accepting my suggestions. Their practical experience highlights their writings, which should build and further the endeavors of the readers in these important areas of disease and injury. I respect and appreciate the hard work and exceptional insight into the nature of cancer provided by these contributors. The contents of the volume are divided into six subheadings: General Introduction, Molecular Genetics, Therapy, Transplantation, Tissue Regeneration, and Apoptosis, for the convenience of the readers.

It is my hope that subsequent volumes of the series will join this volume in assisting in the more complete understanding of the causes, diagnosis, and cell-based treatment of major human diseases and debilitating tissue/organ injuries. There exists a tremendous, urgent demand by the public and the scientific community to address to cancer diagnosis, treatment, cure, and hopefully prevention. In the light of existing cancer calamity, government funding must give priority to eradicating deadly malignancies over military superiority.

I am thankful to Dr. Dawood Farahi and Dr. Kristie Reilly for recognizing the importance of medical research and publishing at an institution of higher education.

Union, New Jersey  
June, 2011

M.A. Hayat

# Contents

## Part I General Introduction

<b>1 Introduction</b> . . . . .	<b>3</b>
M.A. Hayat	
<b>2 Diversity Oriented Fluorescence Library Approach for Stem Cell Probe Development</b> . . . . .	<b>7</b>
Seong-Wook Yun, Nam-Young Kang, and Young-Tae Chang	
<b>3 Isolation of Mesenchymal Stem Cells from Umbilical Cord (Method)</b> . . . . .	<b>15</b>
Katsuhiro Kita, Gerd G. Gauglitz, Stephen Williamson, David N. Herndon, Thang T. Phan, and Marc G. Jeschke	
<b>4 Mesenchymal Stem Cell Isolation and Expansion Methodology</b> . . . . .	<b>23</b>
Mario Ricciardi, Luciano Pacelli, Giulio Bassi, Francesco Bifari, Federico Mosna, and Mauro Krampera	
<b>5 Hair Follicle Stem Cells</b> . . . . .	<b>35</b>
Emilie Legué, Inês Sequeira, and Jean-François Nicolas	
<b>6 Rat Embryonic Cortical Neural Stem Cells: Role of Hypoxia on Cell Proliferation and Differentiation</b> . . . . .	<b>49</b>
Yong Liu, Haixia Lu, and Xinlin Chen	
<b>7 Human Cord Blood-Derived Hematopoietic Stem and Progenitor Cells: From Biology to Medicine</b> . . . . .	<b>63</b>
Hector Mayani	
<b>8 Proteomic Characterization of Mesenchymal Stem Cell-Like Populations Derived from Various Tissue Types</b> . . . . .	<b>75</b>
Krzysztof M. Mrozik, Jimin Xiong, Peter S. Zilm, Stan Gronthos, and P. Mark Bartold	
<b>9 The Roles of Nanog During Early Fish Embryonic Development and Primordial Germ Cell Migration</b> . . . . .	<b>95</b>
Ana V. Sánchez-Sánchez and José L. Mullor	
<b>10 Human Embryonic Stem Cells in Serum-Free Media: Growth and Metabolism</b> . . . . .	<b>103</b>
Steve Oh	

## Part II Molecular Genetics

- 11 Evolutionary Dynamics of Mutations in Hematopoietic Stem Cells and Beyond . . . . . 115**  
David Dingli, Arne Traulsen, and Jorge M. Pacheco
- 12 Isolated Corneal Epithelial Stem Cells Derived from Limbal Biopsies: Use of Lectin as a Marker for Identifying Transient Amplifying Cells . . . . . 125**  
Luciana Dini and Cristian Vergallo
- 13 Stem Cell Distribution and MGMT Expression in Glioblastoma: Role of Intratumoral Hypoxic Gradient . . . . . 139**  
Francesca Pistollato, Alessandro Della Puppa, and Luca Persano
- 14 Initiation of Human Tumourigenesis: Upregulation of FOXM1 Transcription Factor . . . . . 149**  
Muy-Teck Teh

## Part III Therapy

- 15 Role of Cancer Stem Cells of Breast, Colon, and Melanoma Tumors in the Response to Antitumor Therapy . . . . . 157**  
Juan Antonio Marchal, María Angel García, Houria Boulaiz, Macarena Perán, Pablo Álvarez, José Carlos Prados, Consolación Melguizo, and Antonia Aránega
- 16 Cell-Based Regenerative Therapies: Role of Major Histocompatibility Complex-1 Antigen . . . . . 173**  
Alejandra Negro, Cynthia St. Hilaire, and Manfred Boehm
- 17 Mesenchymal Stem Cells For Cellular Therapies . . . . . 179**  
Catarina Madeira, Francisco dos Santos, Pedro Z. Andrade, Cláudia Lobato da Silva, and Joaquim M.S. Cabral
- 18 Radiation Burns and Mesenchymal Stem Cell Therapy . . . . . 189**  
Michel Drouet, Harry Scherthan, Viktor Meineke, and Diane Agay
- 19 Mesenchymal Stem Cells: Role of Mechanical Strain in Promoting Apoptosis and Differentiation . . . . . 199**  
Katey K. McKayed, Patrick J. Prendergast, Veronica A. Campbell, and Aoife Gowran
- 20 Human Mesenchymal Stem Cells: Melatonin as a Potential Anti-osteoporosis Drug . . . . . 207**  
Dongsheng Huang and Liangming Zhang
- 21 Applications of Human Induced Pluripotent Stem Cell Derived Hepatocytes . . . . . 213**  
Hua Liu, Pooja Chaudhari, Su Mi Choi, and Yoon-Young Jang
- 22 Stem Cells and Gastric Carcinogenesis: From Mouse to Human . . . . . 221**  
Sherif M. Karam

<b>23</b>	<b>Gain and Loss of Cancer Stem Cells: Effect on Metastatic Efficiency and Treatment Response</b> . . . . .	<b>231</b>
	Wayne S. Kendal	
<b>24</b>	<b>Treatment of Ischemia/Reperfusion Injury of the Kidney with Mesenchymal Stromal Cells</b> . . . . .	<b>241</b>
	Claudia Lange, Axel R. Zander, and Christof Westenfelder	
<b>25</b>	<b>Mesenchymal Stem Cells: Role for Delivering Nanoparticles to Brain Tumors</b> . . . . .	<b>251</b>
	Mathilde Roger, Anne Clavreul, and Philippe Menei	
<b>26</b>	<b>Human Induced Pluripotent Stem Cells: Role in Patient-Specific Drug Discovery</b> . . . . .	<b>257</b>
	Michael Xavier Doss, Charles Antzelevitch, and Agapios Sachinidis	
<b>27</b>	<b>Biomedical Applications of Induced Pluripotent Stem Cells</b> . . . . .	<b>265</b>
	Vimal Selvaraj	
<b>28</b>	<b>Duchenne Muscular Dystrophy: Isolation of CD133-Expressing Myogenic Progenitors from Blood and Muscle of DMD Patients</b> . . . . .	<b>277</b>
	Mirella Meregalli, Andrea Farini, and Yvan Torrente	
<b>Part IV Transplantation</b>		
<b>29</b>	<b>Human Fetal Mesenchymal Stem Cells for Prenatal and Postnatal Transplantation</b> . . . . .	<b>289</b>
	Mark S.K. Chong and Jerry K.Y. Chan	
<b>30</b>	<b>Protection of Mice from Stroke Using Hematopoietic Stem Cell Transplantation</b> . . . . .	<b>295</b>
	Hady Felfly and Gabriel G. Haddad	
<b>31</b>	<b>Neonatal Hypoxic-Ischemic Encephalopathy: Neural Stem/Progenitor Cell Transplantation</b> . . . . .	<b>305</b>
	Pedro Moreno Pimentel-Coelho and Rosalia Mendez-Otero	
<b>Part V Tissue Regeneration</b>		
<b>32</b>	<b>Mesenchymal Stem Cell-Dependent Formation and Repair of Tendon-Bone Insertions</b> . . . . .	<b>317</b>
	Virginia Seiffart, Sandra Laggies, and Gerhard Gross	
<b>33</b>	<b>Cartilage Injuries: Role of Implantation of Human Stem/Progenitor Cells</b> . . . . .	<b>327</b>
	Yang Zi Jiang, Tong Tong, Boon Chin Heng, and Hong Wei Ouyang	
<b>34</b>	<b>Bone Marrow-Derived Very Small Embryonic-Like Cells: <math>\beta</math>-Cell Regeneration in Pancreatic Tissue</b> . . . . .	<b>335</b>
	Magda Kucia, Yiming Huang, Tomasz Jadczyk, Suzanne T. Ildstad, and Mariusz Z. Ratajczak	
<b>35</b>	<b>Engineering Stem Cell Niche: Regulation of Cellular Morphology and Function</b> . . . . .	<b>345</b>
	Wen Shing Leong, Chor Yong Tay, and Lay Poh Tan	

**Part VI Apoptosis**

<b>36 Embryonic Stem Cells: The Role of Nitric Oxide in Regulating Cell Differentiation, Self-Renewal, and Apoptosis . . .</b>	<b>359</b>
Juan R. Tejedo, Gladys M. Cahuana, Francisco J. Bedoya, and Rafael Tapia-Limonchi	
<b>37 Induction of Apoptosis in Human Keratinocyte Stem Cells: The Role of Hydrogen Sulfide . . . . .</b>	<b>371</b>
Ken Yaegaki, Bogdan Calenic, and Toshio Imai	
<b>Index . . . . .</b>	<b>377</b>

# Contents of Volume 1

- 1 **Pluripotent Human Stem Cells: An Overview**
- 2 **Complexity of Tumor Angiogenesis and Stem Cells**
- 3 **Stem Cells Like Astrocytes: Various Roles**
- 4 **Neural Crest Cell-Derived Tumors: An Overview**
- 5 **Therapeutic Neural Stem Cells for Brain Tumor Therapy**
- 6 **Brain Tumors: Role of Neural Cancer Stem Cells**
- 7 **Targeting Cancer Stem Cells with Phytochemicals:  
Inhibition of the Rat C6 Glioma Side Population by Curcumin**
- 8 **Glioma Patients: Role of CD133 Stem Cell Antigen**
- 9 **Cancer Stem Cells in Brain Gliomas**
- 10 **Primary Glioma Spheroids: Advantage of Serum-Free Medium**
- 11 **Tumorigenesis of Glioma-Initiating Cells: Role of Sox11**
- 12 **Glioma-Initiating Cells: Interferon Treatment**
- 13 **Is CD133 the Appropriate Stem Cell Marker for Glioma?**
- 14 **Cancer Stem Cells in Glioblastoma**
- 15 **Glioblastoma-Derived Cancer Stem Cells: Treatment  
with Oncolytic Viruses**
- 16 **Cancer Stem Cells in Medulloblastoma**
- 17 **Transplantation of Embryonic Stem Cells Results in Reduced  
Brain Lesions**
- 18 **Allogenic Hematopoietic Stem Cell Transplantation  
Followed by Graft-Versus-Host Disease: Role of Adenosine  
A<sub>2A</sub> Receptor**
- 19 **Umbilical Cord Blood and Alpha-3 Fucosyl Transferase-  
Treated Haematopoietic Stem Cells for Transplantation**
- 20 **Bone Marrow-Derived Stem Cell Therapy for Myocardial Infarction**
- 21 **The Use of Mesenchymal Stem Cells in Orthopedics**

# Contents of Volume 2

- 1 Isolation of Bone Marrow Stromal Cells from Bone Marrow by Using a Filtering Device (Method)**
- 2 Hematopoietic Stem Cell Frequency Estimate: Statistical Approach to Model Limiting Dilution Competitive Repopulation Assays**
- 3 Characteristics of Cord Blood Stem Cells: Role of Substance P (SP) and Calcitonin Gene-Related Peptide (CGRP)**
- 4 A New Concept of Stem Cell Disorders, and the Rationale for Transplantation of Normal Stem Cells**
- 5 Differentiation of Human Embryonic Stem Cells into Functional Hepatocyte-Like Cells (Method)**
- 6 Stem Cell Mobilization: An Overview**
- 7 Status and Impact of Research on Human Pluripotent Stem Cells: Cell Lines and Their Use in Published Research**
- 8 Gliosarcoma Stem Cells: Glial and Mesenchymal Differentiation**
- 9 Generation of Induced Pluripotent Stem Cells from Mesenchymal Stromal Cells Derived from Human Third Molars (Method)**
- 10 Self-renewal and Differentiation of Intestinal Stem Cells: Role of Hedgehog Pathway**
- 11 Hematopoietic Stem Cell Repopulation After Transplantation: Role of Vinculin**
- 12 Static and Suspension Culture of Human Embryonic Stem Cells**
- 13 Generation of Marmoset Induced Pluripotent Stem Cells Using Six Transcription Factors (Method)**
- 14 MYC as a Multifaceted Regulator of Pluripotency and Reprogramming**



- 15 **Human Thyroid Cancer Stem Cells**
- 16 **Tumor Stem Cells: CD133 Gene Regulation and Tumor Stemness**
- 17 **Cripto-1: A Common Embryonic Stem Cell and Cancer Cell Marker**
- 18 **Treatment of Heart Disease: Use of Transdifferentiation Methodology for Reprogramming Adult Stem Cells**
- 19 **Rat Mesenchymal Cell CD44 Surface Markers: Role in Cardiomyogenic Differentiation**
- 20 **Stroke Therapy Using Menstrual Blood Stem-Like Cells: Method**
- 21 **Spontaneous Cerebral Stroke in Rats: Differentiation of New Neurons from Neural Stem Cells**
- 22 **Neurogenesis in the Cerebral Cortex After Stroke**
- 23 **Ex Vivo Expanded Hematopoietic Stem Cells for Ischemia**
- 24 **Breast Cancer Risk: Role of Somatic Breast Stem Cells**
- 25 **Cellular Replacement Therapy in Neurodegenerative Diseases Using Induced Pluripotent Stem Cells**
- 26 **Treatment of Graft-Versus-Host Disease Using Allogeneic Mesenchymal Stem Cells**
- 27 **Adult Neurogenesis in Etiology and Pathogenesis of Alzheimer's Disease**
- 28 **Generating Human Cardiac Muscle Cells from Adipose-Derived Stem Cells**
- 29 **Mesenchymal Stem Cells and Mesenchymal-Derived Endothelial Cells: Repair of Bone Defects**
- 30 **Omentum in the Repair of Injured Tissue: Evidence for Omental Stem Cells**
- 31 **Human Embryonic Stem Cells Transplanted into Mouse Retina Induces Neural Differentiation**
- 32 **Stem Cells to Repair Retina: From Basic to Applied Biology**
- 33 **Heterogeneous Responses of Human Bone Marrow Stromal Cells (Multipotent Mesenchymal Stromal Cells) to Osteogenic Induction**
- 34 **Adipose-Derived Stem Cells and Platelet-Rich Plasma: Implications for Regenerative Medicine**
- 35 **Skeletal Muscle-Derived Stem Cells: Role in Cellular Cardiomyoplasty**
- 36 **Cardiac Regenerative Medicine Without Stem Cell Transplantation**

- 
- 37 Allogeneic Transplantation of Fetal Membrane-Derived Mesenchymal Stem Cells: Therapy for Acute Myocarditis**
  - 38 Patients with Cancer or Hematopoietic Stem Cell Transplant: Infection with 2009 H1N1 Influenza**

# Contributors

**Diane Agay** IRBA-CRSSA, 38702 La Tronche, France

**Pablo Álvarez** Departamento de Anatomía y Embriología, Facultad de Medicina, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain

**Pedro Z. Andrade** Department of Bioengineering, Instituto Superior Técnico (IST), 1049-001 Lisboa, Portugal

**Charles Antzelevitch** Masonic Medical Research Laboratory, Utica, NY 13501, USA, ca@mmrl.edu

**Antonia Aránega** Department Anatomía y Embriología, Facultad de Medicina, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain, aranega@ugr.es

**P. Mark Bartold** Colgate Australian Clinical Dental Research Centre, Dental School, The University of Adelaide, Adelaide, SA, Australia

**Giulio Bassi** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy

**Francisco J. Bedoya** Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University Pablo de Olavide, CIBERDEM, Seville 41092, Spain

**Francesco Bifari** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy

**Manfred Boehm** Center for Molecular Medicine, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA, boehmm@nhlbi.nih.gov

**Houria Boulaiz** Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain

**Joaquim M.S. Cabral** Department of Bioengineering, Institute for Biotechnology and Bioengineering (IBB), Centre for Biological and Chemical Engineering, Instituto Superior Técnico, Technical University of Lisbon, Av. Rovisco Pais, 1049-001, Lisboa, Portugal, Joaquim.cabral@ist.utl.pt

**Gladys M. Cahuana** Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University Pablo de Olavide, CIBERDEM, Seville 41092, Spain

**Bogdan Calenic** Department of Oral Health, Nippon Dental University, Chiyoda-Ku, Tokyo 102-8159, Japan

**Veronica A. Campbell** Department of Physiology and Institute of Neuroscience, School of Medicine, Trinity College, University of Dublin, Dublin 2, Ireland; Trinity Centre for Bio-engineering, School of Engineering, Trinity College, University of Dublin, Dublin 2, Ireland

**Jerry K.Y. Chan** Experimental Fetal Medicine Group, Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine, National University of Singapore and National University Hospital System, Singapore 119074, Singapore, jerrychan@nus.edu.sg

**Young-Tae Chang** NUS MedChem Program of Life Sciences Institute, National University of Singapore, Singapore 117543, Singapore; Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A\* STAR), Singapore 138667, Singapore, chmcyt@nus.edu.sg

**Pooja Chaudhari** Stem Cell Biology Laboratory, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

**Xinlin Chen** Institute of Neurobiology, National Key Academic Subject of Physiology, Xi'an Jiaotong University School of Medicine, Xi'an, China

**Su Mi Choi** Stem Cell Biology Laboratory, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

**Mark S.K. Chong** Experimental Fetal Medicine Group, Department of Obstetrics and Gynecology, Yong Loo Lin School of Medicine, National University of Singapore and National University Hospital System, Singapore 119074, Singapore, obgckm@nus.edu.sg

**Anne Clavreul** INSERM Unit 646, IBS-CHU Angers, 4, rue Larrey, Université d'Angers, 49933 Angers, France

**Cláudia Lobato da Silva** Department of Bioengineering, Instituto Superior Técnico (IST), 1049-001, Lisboa, Portugal

**David Dingli** Division of Hematology and Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA, Dingli.david@mayo.edu

**Luciana Dini** Department of Biological and Environmental Science and Technology, University of the Salento, 73100 Lece, Italy, Luciana.dini@unile.it

**Michael Xavier Doss** Stem Cell Center, Masonic Medical Research Laboratory, Utica, NY 13501, USA, Xavier@mmrl.edu

**Francisco dos Santos** Department of Bioengineering, Instituto Superior Técnico (IST), 1049-001 Lisboa, Portugal

**Michel Drouet** Head of Cell Therapy Unit IRBA-CRSSA, 38702 La Tronche, France, micheldrouet@crssa.net

**Andrea Farini** Stem Cell Laboratory, Department of Neurological Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Centro Dino Ferrari, University of Milan, 20122 Milan, Italy

**Hady Felfly** Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093-0735, USA, hadyfelfly@gmail.com

**María Angel García** Unidad de Investigación, Hospital Universitario Virgen de las Nieves, 18100, Granada, Spain; Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100, Granada, Spain

**Gerd G. Gauglitz** Department of Dermatology and Allergology, Ludwig Maximilians University, Munich, Germany

**Aoife Gowran** Department of Physiology and Institute of Neuroscience, School of Medicine, Trinity College, University of Dublin, Dublin 2, Ireland, gowrana@tcd.ie

**Stan Gronthos** Mesenchymal Stem Cell Group, Department of Haematology/Centre for Stem Cell Research, Robinson Institute, Discipline of Medicine, SA Pathology/The University of Adelaide, Adelaide, SA, Australia

**Gerhard Gross** Signaling and Gene Regulation, Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany, gerhard.gross@helmholtz-hzi.de

**Gabriel G. Haddad** Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA 92093-0735, USA

**M.A. Hayat** Department of Biological Sciences, Kean University, Union, NJ 07083, USA, ehayat@kean.edu

**Boon Chin Heng** School of Medicine, Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China

**David N. Herndon** Department of Surgery and Department of Pediatrics, University of Texas, Medical Branch, Shiriners Hospitals for Children, Galveston, TX 77550, USA

**Cynthia St. Hilaire** Center for Molecular Medicine, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA, sthilairec@nhlbi.nih.gov

**Dongsheng Huang** Department of Orthopedics, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, Huangdongsheng18@hotmail.com

**Yiming Huang** Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202, USA

**Suzanne T. Ildstad** Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202, USA, stilds01@louisville.edu

**Toshio Imai** Department of Oral Health, Nippon Dental University, Chiyoda-ku, Tokyo 102-8159, Japan

**Tomasz Jadczyk** Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA

**Yoon-Young Jang** Stem Cell Biology Laboratory, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA, yjang3@jhmi.edu

**Marc G. Jeschke** Department of Surgery, Division of Plastic Surgery, University of Toronto, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada

**Yang Zi Jiang** School of Medicine, Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China

**Nam-Young Kang** Laboratory of Bioimaging Probe Development, Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A\* STAR), Singapore 138667, Singapore

**Sherif M. Karam** Department of Anatomy, Faculty of Medicine and Health Sciences, UAE University, Al-Ain, United Arab Emirates, skaram@uaeu.ac.ae

**Wayne S. Kendal** Division of Radiation Oncology, The Ottawa Hospital Cancer Centre, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, ON, Canada, wkendal@ottawahospital.on.ca

**Katsuhiko Kita** Department of Biochemistry and Molecular Biology, University of Texas, Medical Branch, Galveston, TX 77550, USA, kakitatemp@yahoo.com

**Mauro Krampera** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy, Mauro.krampera@univr.it

**Magda Kucia** Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA

**Sandra Laggies** Inflammation and Regeneration, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany

**Claudia Lange** Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany, cllange@uke.uni-hamburg.de

**Emilie Legué** Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA, leguee@mskcc.org

**Wen Shing Leong** Division of Materials Technology, School of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore

**Hua Liu** Stem Cell Biology Laboratory, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

**Yong Liu** Institute of Neurobiology, National Key Academic Subject of Physiology, Xi'an Jiaotong University School of Medicine, Xi'an, China, Liuy5599@mail.xjtu.edu.cn

**Haixia Lu** Institute of Neurobiology, National Key Academic Subject of Physiology, Xi'an Jiaotong University School of Medicine, Xi'an, China

**Catarina Madeira** Department of Bioengineering, Instituto Superior Técnico (IST), 1049-001 Lisboa, Portugal

**Juan Antonio Marchal** Department Anatomía y Embriología, Facultad de Medicina, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain, [jmarchal@ugr.es](mailto:jmarchal@ugr.es)

**Hector Mayani** Hematopoietic Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center, IMSS, Mexico City, Mexico, [hmayaniv@prodigy.net.mx](mailto:hmayaniv@prodigy.net.mx)

**Katey K. McKayed** Department of Physiology and Institute of Neuroscience, School of Medicine, Trinity College, University of Dublin, Dublin 2, Ireland; Trinity Centre for Bio-engineering, School of Engineering, Trinity College, University of Dublin, Dublin 2, Ireland

**Viktor Meineke** Institut für Radiobiologie der Bundeswehr in Verbindung mit der Universität Ulm, München, Germany

**Consolación Melguizo** Departamento de Anatomía y Embriología, Facultad de Medicina, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain

**Rosalía Mendez-Otero** Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, UFRJ, Rio de Janeiro, RJ 21949-900, Brazil, [rmotero@biof.ufrj.br](mailto:rmotero@biof.ufrj.br)

**Philippe Menei** INSERM Unit 646, IBS-CHU Angers, 4, rue Larrey, Université d'Angers, 49933 Angers, France

**Mirella Meregalli** Stem Cell Laboratory, Department of Neurological Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Centro Dino Ferrari, University of Milan, 20122 Milan, Italy

**Federico Mosna** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy

**Krzysztof M. Mrozik** Colgate Australian Clinical Dental Research Centre, Dental School, The University of Adelaide, Adelaide, SA, Australia, [Krzysztof.mrozik@adelaide.edu.au](mailto:Krzysztof.mrozik@adelaide.edu.au)

**José L. Mullor** Instituto de Investigación Sanitaria Hospital La Fe, 46009 Valencia, Spain, [jlmullor@iislafe.es](mailto:jlmullor@iislafe.es)

**Alejandra Negro** Center for Molecular Medicine, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA, [negroa@mail.nih.gov](mailto:negroa@mail.nih.gov)

**Jean-François Nicolas** Unité de Biologie moléculaire du Développement, Institut Pasteur, 75724 Paris Cedex 15, France, [jfnicola@pasteur.fr](mailto:jfnicola@pasteur.fr)

**Steve Oh** Stem Cell Group, Bioprocessing Technology Institute, Agency for Science Technology and Research (A\*STAR), 06 - 01 Centros, 138668, Singapore, [Steve\\_oh@bti.a-star.edu.sg](mailto:Steve_oh@bti.a-star.edu.sg)

**Hong Wei Ouyang** School of Medicine, Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China, [hwouyang@gmail.com](mailto:hwouyang@gmail.com)

**Luciano Pacelli** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy

**Jorge M. Pacheco** Departamento de Matematica e Aplicações, Universidade do Minho, 4710-057 Braga, Portugal, jorgem.pacheco@gmail.com

**Macarena Perán** Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain

**Luca Persano** Hemato-Oncology Laboratory, Department of Paediatrics, University of Padova, Padova, Italy

**Thang T. Phan** Department of Surgery, Yong Loo Lin School of Medicine and Centre for Craniofacial and Regenerative Biology, National University of Singapore and CellResearch Corp. Pte, Lte, Singapore

**Pedro Moreno Pimentel-Coelho** Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, UFRJ, Rio de Janeiro, RJ 21949-900, Brazil, pedrompc@biof.ufrj.br

**Francesca Pistollato** Hemato-Oncology Laboratory, Department of Paediatrics, University of Padova, Padova, Italy, francesca.pistollato@gmail.com

**José Carlos Prados** Departamento de Anatomía y Embriología, Facultad de Medicina, Institute of Biopathology and Regenerative Medicine (IBIMER), University of Granada, 18100 Granada, Spain

**Patrick J. Prendergast** Trinity Centre for Bio-engineering, School of Engineering, Trinity College, University of Dublin, Dublin 2, Ireland

**Alessandro Della Puppa** Department of Neurosurgery, University of Padova, Padova, Italy

**Mariusz Z. Ratajczak** Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA, mzrata01@louisville.edu

**Mario Ricciardi** Stem Cell Research Laboratory, Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy

**Mathilde Roger** INSERM Unit 646, IBS-CHU Angers, 4, rue Larrey, Université d'Angers, 49933 Angers, France, Mathilde.roger@yahoo.fr

**Agapios Sachinidis** Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne, 50931, Cologne, Germany, a.sachinidis@uni-koeln.de

**Ana V. Sánchez-Sánchez** Instituto de Investigación Sanitaria Hospital La Fe, 46009 Valencia, Spain

**Harry Scherthan** Institut für Radiobiologie der Bundeswehr in Verbindung mit der Universität Ulm, München, Germany

**Virginia Seiffart** Inflammation and Regeneration, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany

**Vimal Selvaraj** Department of Animal Science, Cornell University, Ithaca, NY 14853, USA, vs88@cornell.edu

**Inês Sequeira** Unité de Biologie moléculaire du Développement, Institut Pasteur, 75724 Paris Cedex 15, France, sequeira@pasteur.fr



**Lay Poh Tan** Division of Materials Technology, School of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore, lptan@ntu.edu.sg

**Rafael Tapia-Limonchi** Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University Pablo de Olavide, CIBERDEM, Seville 41092, Spain

**Chor Yong Tay** Division of Materials Technology, School of Materials Science and Engineering, Nanyang Technological University, Singapore 639798, Singapore

**Muy-Teck Teh** Barts and The London School of Medicine and Dentistry, The Blizard Institute of Cell and Molecular Science Building, Centre for Clinical and Diagnostic Oral Sciences, Queen Mary University of London, London E1 2AT, UK, m.t.teh@qmul.ac.uk

**Juan R. Tejedo** Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University Pablo de Olavide, CIBERDEM, Seville 41092, Spain, Juan.tejedo@cabimer.es

**Tong Tong** School of Medicine, Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China

**Yvan Torrente** Stem Cell Laboratory, Department of Neurological Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Centro Dino Ferrari, University of Milan, 20122 Milan, Italy, Yvan.torrente@unimi.it

**Arne Traulsen** Evolutionary Theory Group, Max Planck Institute for Evolutionary Biology, Plön, Germany, traulsen@evolbio.mpg.de

**Cristian Vergallo** Department of Biological and Environmental Science and Technology, University of the Salento, 73100 Lece, Italy

**Christof Westenfelder** Division of Nephrology (111N), George E. Wahlen Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA

**Stephen Williamson** Shriners Hospitals for Children, Galveston, TX 77550, USA

**Jimin Xiong** Colgate Australian Clinical Dental Research Centre, Dental School, The University of Adelaide, Adelaide, SA, Australia

**Ken Yaegaki** Department of Oral Health, Nippon Dental University, Chiyoda-ku, Tokyo 102-8159, Japan, Yaegaki-k@tky.ndu.ac.jp

**Seong-Wook Yun** Laboratory of Bioimaging Probe Development, Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A\* STAR), Singapore 138667, Singapore

**Axel R. Zander** Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany

**Liangming Zhang** Department of Orthopedics, Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

**Peter S. Zilm** Colgate Australian Clinical Dental Research Centre, Dental School, The University of Adelaide, Adelaide, SA, Australia

**Part I**  
**General Introduction**

# Chapter 1

## Introduction

M.A. Hayat

It is recognized that scientific journals and books not only provide current information but also facilitate exchange of information, resulting in rapid progress in the medical field. In this endeavor, the main role of scientific books is to present current information in more detail after careful additional evaluation of the investigational results, especially those of new or relatively new therapeutic methods and their potential toxic side-effects.

Although subjects of tissue repair, diagnosis, cancer recurrence, resistance to chemotherapy, assessment of treatment effectiveness, including cell therapy and side-effects of a treatment are scattered in a vast number of journals and books, there is need of combining these subjects into single volumes. An attempt will be made to accomplish this goal in the projected seven-volume series of Handbooks.

In the era of cost-effectiveness, my opinion may be minority perspective, but it needs to be recognized that the potential for false-positive or false-negative interpretation on the basis of a single laboratory test in clinical pathology does exist. Interobserver or intraobserver variability in the interpretation of results in pathology is not uncommon. Interpretative differences often are related to the relative importance of the criteria being used.

Generally, no test always performs perfectly. Although there is no perfect remedy to this problem, standardized classifications with written definitions and guidelines will help. Standardization of

methods to achieve objectivity is imperative in this effort. The validity of a test should be based on the careful, objective interpretation of the tomographic images, photomicrographs, and other tests. The interpretation of the results should be explicit rather than implicit. To achieve accurate diagnosis and correct prognosis, the use of molecular criteria and targeted medicine is important. Equally important are the translation of molecular genetics into clinical practice and evidence-based therapy. Translation of medicine from the laboratory to clinical application needs to be carefully expedited. Indeed, molecular medicine has arrived.

Although current cancer treatment methods have had an important impact on cancer-related morbidity and mortality, the cure rates are modest. On the other hand, cell-based therapy has the potential to treat human conditions not treatable with available pharmaceutical agents, radiation, surgery, chemotherapy or hormonal therapy. Stem cells present important opportunities to elucidate manifold aspects of molecular biology and potential therapeutic strategies, especially in the areas of cancer and tissue/organ injuries. In other words, the stem cell field has tremendous potential in deciphering the molecular pathways involved in human diseases. Some stem cell therapies already are being clinically used routinely; for example in leukemic therapy. Human stem cells also have the potential for application in regenerative medicine, tissue engineering, and in vitro applications in drug discovery and toxicity testing. Stem cells represent populations of primal cells found in all multicellular organisms, which have the capacity to form a variety of different cell types.

Adult stem cells maintain populations of highly differentiated and short-lived cells throughout the life of

---

M.A. Hayat (✉)  
Department of Biological Sciences, Kean University, Union,  
NJ 07083, USA  
e-mail: ehayat@kean.edu

the organism. Thus, the life-long importance of stem cells becomes apparent considering that they allow blood, bone, gametes, epithelia, nervous system, muscle, skin, and many other tissues to be replenished by fresh cells throughout life. Additional stem cells remain dormant, but can be activated at specific life cycle stages or following injury. The importance of stem cells in the life of humans can be summed up by stating that these cells are nature's indispensable gift to multicellular organisms.

Many adult stem cells often divide asymmetrically to balance self-renewal and differentiation, maintaining tissue homeostasis. Asymmetric stem cell divisions depend on cell polarity within the cell and/or its microenvironment (niche). Stem cell niches are specialized, restricted tissue compartments that help to maintain multipotent stem cell populations. Within the niche, a stem cell divides asymmetrically, giving rise to one stem cell and one differentiating cell, by placing one daughter cell inside and another outside of the niche, respectively. However, some stem cells divide asymmetrically without the optimal niche. The asymmetric outcome of stem cell division can be specified by regulated spindle orientation, such that the two daughter cells are placed in different microenvironments that specify either stem cell identity or allow differentiation. Stem cells are also capable of dividing symmetrically, producing two stem cells. This property is an important mechanism for stem cell explanation during embryonic development and replacement of stem cells after injury.

A brief statement on the difference between tissue specific stem cells and embryonic stem cells is in order. Tissue specific stem cells (adult or somatic stem cell) can be isolated from a range of organs and tissues from fetal or adult organisms. These cells have a limited life span, senescence during in vitro propagation, and are multipotent; thus, they can be differentiated into a limited number of specialized cells. Embryonic stem cells, on the other hand, are isolated from the inner cell mass of a fertilized egg that has been cultured in vitro to match the blastocyte stage (5–7 days post-fertilization). These cells possess infinite capacity to proliferate in vitro, providing the maintenance in an appropriate condition. The advantage of these cells is that they are pluripotent and can give rise to any fetal or adult cell type.

## **Characteristics of Different Types of Stem Cells**

### ***Embryonic Stem Cells***

Embryonic stem cells can be maintained in in vitro culture conditions as established cell lines. Human embryonic stem cells are pluripotent and possess the capacity to differentiate into virtually every cell type found in the human body. They can be characterized by a distinct set of cell surface markers as well as marker genes for pluripotency. When human embryonic stem cells are transplanted into a permissive host, they form teratomas which are benign tumors consisting of various cell types derived from all three layers: endoderm, ectoderm, and mesoderm. Human embryonic stem cells can be differentiated in vitro using either an external factor in the culture medium or by genetic modification. However, in vitro differentiation often generates cell populations having varying degrees of heterogeneity.

### ***Mesenchymal Stem Cells***

Mesenchymal stem cells are primarily derived from bone marrow stroma or adipose tissue. These cells have also been isolated from many other tissue types, such as retina, liver, gastric epithelium, tendons, synovial membrane, placenta, umbilical cord, and blood. Mesenchymal stem cells have a multilineage differentiation capacity and can be directed towards, for example, chondrogenic, osteogenic, and adipogenic cell lineages. These cells can also be differentiated into neurons, astrocytes, tenocytes, and skeletal myocytes.

### ***Hematopoietic Stem Cells***

Hematopoietic stem cells are able to give rise to differentiated cells of all hematopoietic lineages, myeloid and lymphoid, either in the hematopoietic bone marrow or in the thymus. In the adult body, hematopoietic stem cells are located in the bone marrow and found, at a lower frequency, circulating in the peripheral blood. At a low frequency, they may also be found in other

tissues (e.g., liver, spleen, and muscle). Hematopoietic stem cells are mobilized to the blood compartment after treatments with intensive chemotherapy and/or growth factors. These stem cells are found in the placental and cord blood at birth in concentrations similar to those in the adult bone marrow.

### ***Tissue Specific Stem Cells***

Tissue specific stem cells have a more limited differentiation capacity and normally produce a single cell type or a few cell types that are specific to that tissue.

### ***Induced Pluripotent Stem Cells***

Induced pluripotent stem cells are artificially generated stem cells. They are reprogrammed from somatic adult cells such as skin fibroblasts. These cells share many features of human embryonic stem cells. Induced pluripotent stem cells have self-renewing capacity, are pluripotent, and form teratomas. These cells are being

increasingly produced from different adult cell types. The differentiation capacity of induced pluripotent stem cells depends on the cell type and age of the cells from which they are reprogrammed.

A word of caution is appropriate before a decision is made to use stem cell-based intervention. Although stem cell therapy holds great promise for a large number of currently incurable diseases and tissue injuries, patients should be made aware of the possible risks and benefits of this treatment. Development of graft-versus-host disease following, for example, hematopoietic stem cell transplantation is well known. Long-term survivors of hematopoietic cell transplantation present a host of other chronic and debilitating conditions attributed to toxicity from pretransplantation exposure, transplantation conditioning regimens, infections, immunodeficiency, and congestive heart failure. Guidelines for the conduct of human embryonic stem cell research are available at (<http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf>). Relevant information can also be obtained from the International Stem Cell Forum (<http://www.stemcellforum.org/index.cfm>).

## Chapter 2

# Diversity Oriented Fluorescence Library Approach for Stem Cell Probe Development

Seong-Wook Yun, Nam-Young Kang, and Young-Tae Chang

**Abstract** Directed differentiation of stem cells and reprogramming of somatic cells into stem cells are the key issues in stem cell research and regenerative medicine. The most demanding requisites in the basic research and clinical applications of stem cells is to develop tools and methodologies for detecting and isolating specific type of stem cells at different stages of differentiation and reprogramming. Bioimaging which employs highly sophisticated imaging probes is becoming an emerging and rapidly growing field in biomedicine. Although stem cells have been visualized by various imaging techniques including fluorescence, luminescence, MRI, PET, and SPECT, the development of more specific and reliable imaging probes is an unmet need. Optical imaging techniques employing fluorescence have particular advantages in terms of detectability, efficiency and applicability in the bioimaging probe development. Using combinatorial chemistry, we have developed Diversity Oriented Fluorescence Library (DOFL) composed of intrinsically fluorescent small molecule collections. The power of DOFL approach has been demonstrated by the development of sensors and imaging probes for DNA, RNA, GTP, human serum albumin, glutathione, heparin, beta amyloid plaque and differentiated muscle cell. These successful results demonstrate that the DOFL can be applied, due to the unbiased structural diversity, to the screening of various analytes

thus maximizing the chance of successful development of bioimaging probes. By screening a diversity oriented rosamine library, we developed the first fluorescent pluripotent stem cell probe CDy1, which also detects the cells undergoing reprogramming into induced pluripotent stem cells.

**Keywords** DOFL · CDy1 · Superparamagnetic iron oxide · SPECT · PET · Luminescence

## Introduction

Stem cells have emerged as an invaluable tool for cell-based therapy and the generation of human disease model systems for drug discovery and pathogenesis research. Controlling and monitoring the differentiation of stem cells into specific type of cells or reprogramming of somatic cells into stem cells are the key techniques in stem cell research field. A number of biological pathways and small molecules have been discovered to control stem cell differentiation and somatic cell reprogramming into stem cells (Cohen and Melton, 2011; Plath and Lowry, 2011). If the functions of proteins or small molecules are revealed by in vitro experiments, their roles need to be confirmed in the ex vivo and finally in vivo systems to be properly interpreted, as the behaviors of small molecule, macro molecules and even cells in vivo are affected by many conditions that cannot be reproduced in in vitro experimental settings. For non-invasive investigation, which is required for the experiments in living biological systems, imaging technology is especially desirable. Both optical and nuclear imaging for live cell investigation depend on the development of labeling reagents

---

Y.-T. Chang (✉)

NUS MedChem Program of Life Sciences Institute, National University of Singapore, Singapore 117543

Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A\* STAR), Singapore 138667  
e-mail: chmcyt@nus.edu.sg